PreTRM® Test
Risk assessment for spontaneous preterm birth in asymptomatic singleton pregnancies
Approved/CommercialMarketed
Key Facts
Indication
Risk assessment for spontaneous preterm birth in asymptomatic singleton pregnancies
Phase
Approved/Commercial
Status
Marketed
Company
About Sera Prognostics
Sera Prognostics, operating as 'The Pregnancy Company,' is a public company dedicated to transforming prenatal care through innovative diagnostics. Its core technology is a proteomic biomarker-based test (PreTRM) that identifies a pregnant individual's personalized risk of preterm birth, enabling targeted interventions. The company is commercializing PreTRM in the U.S., supported by clinical data showing its use can reduce severe neonatal morbidity and mortality, and is developing additional products like the LikeMine™ data platform to expand its offerings in women's health.
View full company profile